PMID- 26944210 OWN - NLM STAT- MEDLINE DCOM- 20160808 LR - 20191210 IS - 1872-7980 (Electronic) IS - 0304-3835 (Linking) VI - 375 IP - 1 DP - 2016 May 28 TI - Cotreatment with Smac mimetics and demethylating agents induces both apoptotic and necroptotic cell death pathways in acute lymphoblastic leukemia cells. PG - 127-132 LID - S0304-3835(16)30108-2 [pii] LID - 10.1016/j.canlet.2016.02.040 [doi] AB - Treatment resistance in acute lymphoblastic leukemia (ALL) is often caused by defects in programmed cell death, e.g. by overexpression of Inhibitor of Apoptosis (IAP) proteins. Here, we report that small-molecule Smac mimetics (i.e. BV6, LCL161, birinapant) that neutralize x-linked IAP (XIAP), cellular IAP (cIAP)1 and cIAP2 cooperate with demethylating agents (i.e. 5-azacytidine (5AC) or 5-aza-2'-deoxycytidine (DAC)) to induce cell death in ALL cells. Molecular studies reveal that induction of cell death is preceded by BV6-mediated depletion of cIAP1 protein and involves tumor necrosis factor (TNF)alpha autocrine/paracrine signaling, since the TNFalpha-blocking antibody Enbrel significantly reduces BV6/5AC-induced cell death. While BV6/5AC cotreatment induces caspase-3 activation, the broad-range caspase inhibitor N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone (zVAD.fmk) only partly rescues ALL cells from BV6/5AC-induced cell death. This indicates that BV6/5AC cotreatment engages non-apoptotic cell death upon caspase inhibition. Indeed, genetic silencing of key components of necroptosis such as Receptor-Interacting Protein (RIP)3 or mixed lineage kinase domain-like (MLKL) in parallel with administration of zVAD.fmk provides a significantly better protection against BV6/5AC-induced cell death compared to the use of zVAD.fmk alone. Similarly, concomitant administration of pharmacological inhibitors of necroptosis (i.e. necrostatin-1s, GSK'872, dabrafenib, NSA) together with zVAD.fmk is superior in rescuing cells from BV6/5AC-induced cell death compared to the use of zVAD.fmk alone. These findings demonstrate that in ALL cells BV6/5AC-induced cell death is mediated via both apoptotic and necroptotic pathways. Importantly, BV6/5AC cotreatment triggers necroptosis in ALL cells that are resistant to apoptosis due to caspase inhibition. This opens new perspectives to overcome apoptosis resistance with important implications for the development of new treatment strategies for ALL. CI - Copyright (c) 2016 Elsevier Ireland Ltd. All rights reserved. FAU - Gerges, Steve AU - Gerges S AD - Institute for Experimental Cancer Research in Pediatrics, Goethe-University, Komturstr. 3a, 60528 Frankfurt, Germany. FAU - Rohde, Katharina AU - Rohde K AD - Institute for Experimental Cancer Research in Pediatrics, Goethe-University, Komturstr. 3a, 60528 Frankfurt, Germany. FAU - Fulda, Simone AU - Fulda S AD - Institute for Experimental Cancer Research in Pediatrics, Goethe-University, Komturstr. 3a, 60528 Frankfurt, Germany; German Cancer Consortium (DKTK), Heidelberg, Germany; German Cancer Research Center (DKFZ), Heidelberg, Germany. Electronic address: simone.fulda@kgu.de. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20160302 PL - Ireland TA - Cancer Lett JT - Cancer letters JID - 7600053 RN - 0 (Antineoplastic Agents) RN - 0 (Apoptosis Regulatory Proteins) RN - 0 (BV6 peptide) RN - 0 (DIABLO protein, human) RN - 0 (Intracellular Signaling Peptides and Proteins) RN - 0 (Mitochondrial Proteins) RN - 0 (Oligopeptides) RN - EC 2.7.- (MLKL protein, human) RN - EC 2.7.- (Protein Kinases) RN - EC 2.7.11.1 (RIPK3 protein, human) RN - EC 2.7.11.1 (Receptor-Interacting Protein Serine-Threonine Kinases) RN - EC 3.4.22.- (Caspases) RN - M801H13NRU (Azacitidine) SB - IM MH - Antineoplastic Agents/*pharmacology MH - Apoptosis MH - Apoptosis Regulatory Proteins MH - Azacitidine/*pharmacology MH - Caspases/metabolism MH - Cell Line, Tumor MH - Drug Screening Assays, Antitumor MH - Drug Synergism MH - Gene Knockdown Techniques MH - Humans MH - Intracellular Signaling Peptides and Proteins/pharmacology MH - Mitochondrial Proteins/pharmacology MH - Molecular Mimicry MH - Necrosis MH - Oligopeptides/*pharmacology MH - Precursor Cell Lymphoblastic Leukemia-Lymphoma/*drug therapy MH - Protein Kinases/genetics/metabolism MH - Receptor-Interacting Protein Serine-Threonine Kinases/genetics/metabolism OTO - NOTNLM OT - Apoptosis OT - Demethylating agents OT - Leukemia OT - Necroptosis OT - Smac EDAT- 2016/03/06 06:00 MHDA- 2016/08/09 06:00 CRDT- 2016/03/06 06:00 PHST- 2016/01/12 00:00 [received] PHST- 2016/02/17 00:00 [revised] PHST- 2016/02/19 00:00 [accepted] PHST- 2016/03/06 06:00 [entrez] PHST- 2016/03/06 06:00 [pubmed] PHST- 2016/08/09 06:00 [medline] AID - S0304-3835(16)30108-2 [pii] AID - 10.1016/j.canlet.2016.02.040 [doi] PST - ppublish SO - Cancer Lett. 2016 May 28;375(1):127-132. doi: 10.1016/j.canlet.2016.02.040. Epub 2016 Mar 2.